- Home
- DYN vs CORT Comparison
DYN vs CORT Comparison
Compare DYN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- CORT
- Stock Information
- Founded
- DYN 1984
- CORT 1998
- Country
- DYN United States
- CORT United States
- Employees
- DYN N/A
- CORT N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- DYN Health Care
- CORT Health Care
- Exchange
- DYN Nasdaq
- CORT Nasdaq
- Market Cap
- DYN 3.4B
- CORT 4.0B
- IPO Year
- DYN 2020
- CORT N/A
- Fundamental
- Price
- DYN $28.39
- CORT $51.83
- Analyst Decision
- DYN Strong Buy
- CORT Strong Buy
- Analyst Count
- DYN 9
- CORT 4
- Target Price
- DYN $52.44
- CORT $75.25
- AVG Volume (30 Days)
- DYN 1.0M
- CORT 1.2M
- Earning Date
- DYN 11-12-2024
- CORT 10-30-2024
- Dividend Yield
- DYN N/A
- CORT N/A
- EPS Growth
- DYN N/A
- CORT 57.97
- EPS
- DYN N/A
- CORT 1.26
- Revenue
- DYN N/A
- CORT $628,555,000.00
- Revenue This Year
- DYN N/A
- CORT $46.29
- Revenue Next Year
- DYN N/A
- CORT $17.09
- P/E Ratio
- DYN N/A
- CORT $41.11
- Revenue Growth
- DYN N/A
- CORT 39.67
- 52 Week Low
- DYN $9.82
- CORT $20.84
- 52 Week High
- DYN $47.45
- CORT $61.66
- Technical
- Relative Strength Index (RSI)
- DYN 42.04
- CORT 52.64
- Support Level
- DYN $27.99
- CORT $42.01
- Resistance Level
- DYN $35.68
- CORT $61.66
- Average True Range (ATR)
- DYN 2.09
- CORT 3.27
- MACD
- DYN 0.23
- CORT -0.03
- Stochastic Oscillator
- DYN 9.12
- CORT 49.97
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.